Genomic Analysis of Osteocyte-Derived Extracellular Matrix Remodeling During Bone Aging

Abstract

Bone aging is characterized by declining mass, impaired material quality, altered remodeling, and increasing susceptibility to fragility fractures. Osteocytes, the most abundant and longest-lived bone cells, are central regulators of these processes because they coordinate mineral homeostasis, mechanosensation, remodeling signals, and extracellular matrix maintenance. Their activity is influenced not only by cellular senescence and changes in canalicular connectivity but also by age-associated genomic and epigenomic alterations. Genomic analysis of osteocyte-derived extracellular matrix remodeling provides a framework for understanding how transcriptional programs, noncoding RNAs, chromatin states, and cell-to-cell signaling modify collagen organization, mineral deposition, matrix repair, and skeletal adaptation. Emerging single-cell, spatial transcriptomic, proteomic, and computational approaches have identified heterogeneous osteocyte populations with distinct signatures related to bone formation, resorption, inflammation, vascular interaction, and senescence. These findings may support earlier identification of skeletal fragility, development of mechanism-based biomarkers, and therapeutic strategies that preserve osteocyte viability and matrix competence. Translation into clinical practice will require standardized sampling, longitudinal validation, and integration of genomic findings with bone density, microarchitecture, fracture history, and systemic risk factors.

Introduction

Bone is a dynamic organ in which mineralized extracellular matrix is continuously produced, modified, and removed. Osteocytes arise from osteoblasts that become embedded in newly formed matrix and extend dendritic processes through the lacunocanalicular network. Although historically considered relatively inactive, osteocytes are now recognized as essential regulators of bone remodeling, phosphate metabolism, mechanical adaptation, and the coupling of osteoblast and osteoclast activity. During aging, osteocytes experience oxidative stress, reduced nutrient exchange, altered mechanical loading, mitochondrial dysfunction, and progressive loss of dendritic integrity. These changes influence both the cells and the matrix that surrounds them.

Genomic analysis has expanded the study of skeletal aging beyond conventional measurements such as bone mineral density. Osteocyte transcriptional programs can regulate sclerostin, receptor activator of nuclear factor kappa-B ligand, fibroblast growth factor 23, matrix proteins, proteases, and signaling mediators involved in Wnt, transforming growth factor beta, insulin-like growth factor, and inflammatory pathways. Analysis of these programs may explain why individuals with comparable bone density can have markedly different fracture risks. It also provides clinically relevant insight into the biological basis of impaired bone quality, delayed repair, and treatment resistance in older adults.

Epidemiology / Disease Burden

Age-related skeletal fragility is a major public health problem, particularly in postmenopausal women and older men. Osteoporosis and osteopenia affect hundreds of millions of people worldwide, and fragility fractures of the hip, vertebrae, wrist, and proximal humerus are associated with pain, disability, loss of independence, institutionalization, and increased mortality. The burden is amplified by population aging, reduced physical activity, vitamin D insufficiency, multimorbidity, and underdiagnosis of osteoporosis after an initial fracture.

Bone mineral density declines with age, but fracture risk also reflects cortical porosity, trabecular perforation, altered collagen cross-linking, accumulated microdamage, and reduced repair capacity. Osteocyte dysfunction contributes to each of these features by disrupting targeted remodeling and mechanotransduction. Genomic studies suggest that aging changes the proportion and function of osteocyte subpopulations, including cells associated with matrix production, perilacunar remodeling, immune signaling, and mineral metabolism. These findings support a disease-burden model in which skeletal aging is not simply a quantitative loss of bone but a progressive deterioration of cellular and matrix quality.

Pathophysiology

Osteocyte-derived matrix remodeling involves coordinated regulation of collagen turnover, noncollagenous proteins, mineral crystal organization, and the local composition of the perilacunar and pericanalicular matrix. Osteocytes can modify their immediate matrix through enzymes involved in demineralization and remineralization, allowing adaptation to mechanical demands and mineral requirements. With advancing age, this process becomes less coordinated. Reduced expression of matrix-related genes, altered protease activity, accumulation of advanced glycation end products, and changes in mineral crystallinity may increase stiffness while reducing toughness.

Genomic investigations have identified age-associated changes in pathways governing Wnt signaling, sclerostin production, osteoblast-osteoclast coupling, apoptosis, autophagy, and cellular senescence. Increased inflammatory signaling may enhance expression of cytokines and chemokines that stimulate osteoclastogenesis, whereas impaired Wnt activity may reduce osteoblast recruitment and matrix synthesis. Epigenetic modifications, including altered DNA methylation, histone regulation, and microRNA expression, can stabilize maladaptive transcriptional states. Mitochondrial genomic stress and defective quality-control pathways may further promote reactive oxygen species production and osteocyte apoptosis.

Single-cell and spatial analyses indicate that osteocytes are heterogeneous rather than transcriptionally uniform. Some populations retain matrix-maintenance and mechanosensory functions, whereas others exhibit signatures of senescence, inflammation, hypoxia, or mineral-regulatory activity. Spatial context is important because osteocytes near vascular channels, remodeling surfaces, or microcracks may receive different mechanical and biochemical signals. The interaction between osteocytes, endothelial cells, osteoblast-lineage cells, osteoclasts, and immune cells therefore shapes the final matrix phenotype.

Risk Factors

Major clinical risk factors for osteocyte dysfunction and matrix deterioration include advanced age, estrogen deficiency, low testosterone, chronic glucocorticoid exposure, chronic kidney disease, diabetes, malnutrition, smoking, excess alcohol use, inflammatory disease, immobilization, and insufficient mechanical loading. Recurrent falls and sarcopenia increase fracture risk even when genomic or structural bone abnormalities are modest. Vitamin D deficiency and disturbances of calcium, phosphate, or parathyroid hormone regulation may intensify osteocyte stress and disrupt mineral homeostasis.

Genetic susceptibility also contributes. Variants affecting Wnt signaling, collagen structure, phosphate regulation, antioxidant defenses, and bone remodeling can modify the response to aging or therapy. However, genetic predisposition is influenced by epigenetic and environmental factors, and no single genomic marker currently provides adequate clinical prediction for most patients. A comprehensive assessment should therefore combine family history, medications, endocrine status, lifestyle, fracture history, bone density, and measures of fall risk.

Clinical Features

Osteocyte-centered matrix dysfunction is usually clinically silent until structural deterioration produces a fragility fracture. Patients may present with vertebral compression fractures, progressive height loss, kyphosis, back pain, hip pain after a low-energy fall, or reduced mobility. Some individuals develop fractures despite bone mineral density values that are not within the osteoporotic range, reflecting compromised cortical porosity, trabecular connectivity, or matrix quality. Delayed fracture healing and atypical responses to mechanical loading may also indicate impaired cellular adaptation.

Clinical manifestations may be accompanied by sarcopenia, frailty, recurrent falls, poor balance, or reduced exercise tolerance. These features are not specific to osteocyte dysfunction but identify patients in whom skeletal matrix abnormalities can have greater consequences. Recognition of vertebral fractures, including clinically silent fractures detected on vertebral imaging, is particularly important because such fractures substantially increase subsequent fracture risk.

Diagnosis

Current diagnosis relies on dual-energy X-ray absorptiometry, vertebral fracture assessment, radiography, and validated clinical risk algorithms. Bone mineral density remains useful for estimating fracture probability and guiding treatment, but it does not directly measure osteocyte genomic activity or extracellular matrix quality. High-resolution peripheral quantitative computed tomography and advanced magnetic resonance methods can provide information about cortical porosity, trabecular structure, and microarchitecture in research and selected clinical settings.

Circulating markers such as procollagen type 1 N-terminal propeptide, beta-isomerized C-terminal telopeptide, sclerostin, and fibroblast growth factor 23 may offer indirect information about bone turnover or osteocyte-related signaling, although their interpretation is affected by renal function, treatment, circadian variation, and assay differences. Genomic approaches currently remain investigational. Tissue transcriptomics, single-cell sequencing, spatial profiling, and extracellular vesicle RNA analysis may eventually identify signatures associated with accelerated skeletal aging, but clinical use requires reproducible thresholds, standardized specimen handling, and prospective validation against fracture outcomes.

Treatment & Management

Management should follow established osteoporosis principles while addressing the biological and functional contributors to skeletal aging. Adequate dietary calcium, correction of vitamin D deficiency, protein sufficiency, resistance and weight-bearing exercise, balance training, smoking cessation, moderation of alcohol intake, and fall-prevention interventions are foundational. Exercise may be particularly relevant to osteocyte biology because mechanical loading influences osteocyte signaling and matrix adaptation, although programs must be individualized for fracture risk and physical capacity.

Pharmacological therapy is selected according to fracture probability, prior fractures, renal function, comorbidities, and treatment history. Antiresorptive agents reduce bone loss and fracture risk by suppressing excessive remodeling, while anabolic or bone-forming therapies can stimulate matrix production in appropriately selected patients with very high fracture risk. Denosumab, bisphosphonates, teriparatide, abaloparatide, and romosozumab have distinct effects on remodeling pathways and require attention to sequencing, treatment duration, adherence, and discontinuation planning. No approved treatment currently targets the complete genomic program of osteocyte-derived matrix remodeling. Therapies that preserve osteocyte viability, reduce senescence, restore mechanotransduction, or normalize matrix-specific transcription remain areas of investigation.

Recent Advances / Emerging Therapies

Recent advances include single-cell RNA sequencing, spatial transcriptomics, chromatin accessibility profiling, and integrated proteogenomic analysis of aging bone. These methods can distinguish osteocyte states that are obscured in bulk tissue analysis and can map transcriptional changes to specific anatomical niches. Computational integration with clinical phenotypes may identify molecular subgroups with different fracture trajectories or treatment responses. Extracellular vesicles released by osteocytes are also being studied as carriers of microRNAs and proteins that influence distant bone cells and potentially provide minimally invasive biomarkers.

Emerging therapeutic concepts include senolytic or senomorphic strategies, targeted modulation of sclerostin and Wnt signaling, mitochondrial protection, epigenetic reprogramming, and delivery of regulatory nucleic acids to osteocyte-lineage cells. Tissue-engineered matrices and biomaterials may be designed to reproduce mechanical and biochemical cues that support osteocyte maturation and matrix repair. These approaches face important barriers, including efficient skeletal delivery, avoidance of abnormal bone formation, immune effects, off-target gene regulation, and the need to preserve the normal balance between formation and resorption.

Guideline Recommendations

Current professional guidelines recommend fracture-risk assessment using clinical factors, bone mineral density, and validated risk tools, followed by pharmacological treatment for patients meeting established diagnostic or risk thresholds. Individuals with a hip or vertebral fragility fracture generally warrant prompt evaluation and, in many cases, treatment regardless of bone mineral density. Guidelines also emphasize calcium and vitamin D adequacy, exercise, fall prevention, medication review, secondary-cause assessment, and monitoring of adherence and response.

Genomic testing of osteocyte-derived matrix remodeling is not yet recommended for routine osteoporosis diagnosis or treatment selection. Clinicians should interpret commercially available molecular panels cautiously unless they have undergone rigorous analytical and clinical validation. Research findings should complement, rather than replace, fracture history, imaging, laboratory evaluation, and individualized risk assessment. Future guideline updates may incorporate molecular biomarkers if prospective studies demonstrate that they improve prediction, guide treatment choice, or identify clinically actionable stages of skeletal aging.

Conclusion

Genomic analysis of osteocyte-derived extracellular matrix remodeling has clarified that bone aging is a multifaceted process involving altered cellular states, mechanotransduction, mineral regulation, matrix turnover, inflammation, and epigenetic control. Osteocyte heterogeneity and spatial organization provide important explanations for differences in bone quality and fracture susceptibility that are not captured by bone mineral density alone. At present, clinical care should continue to rely on validated fracture-risk assessment, imaging, lifestyle intervention, and evidence-based pharmacotherapy. Continued integration of genomics, spatial biology, proteomics, and longitudinal clinical data may produce reliable biomarkers and targeted treatments that preserve osteocyte function, improve matrix quality, and reduce age-related skeletal fragility.